Abstract: The disclosure relates to methods of treating multiple sclerosis. Also provided are pharmaceutical products containing ponesimod, instructions for use of ponesimod, methods for selling a drug product containing ponesimod, and methods for reducing clinical management events before or during treatment of multiple sclerosis.
Type:
Grant
Filed:
October 10, 2022
Date of Patent:
April 9, 2024
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Allitia DiBernardo, Tatiana Sidorenko, Michel Burcklen, Sivi Ouwerkerk-Mahadevan, Andrea Vaclavkova, Brian Patrick Hennessy, Hilke Kracker
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Grant
Filed:
March 14, 2023
Date of Patent:
March 5, 2024
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Grant
Filed:
February 15, 2022
Date of Patent:
March 5, 2024
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Grant
Filed:
February 15, 2022
Date of Patent:
December 26, 2023
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem repeat (VNTR) genotype.
Type:
Grant
Filed:
May 21, 2021
Date of Patent:
December 19, 2023
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Christian N. Lavedan, Mihael H. Polymeropoulos, Gunther P. Birznieks
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Grant
Filed:
March 19, 2021
Date of Patent:
December 5, 2023
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Grant
Filed:
February 15, 2022
Date of Patent:
November 28, 2023
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: The disclosure provides methods and compositions for the treatment of PDE IV-mediated diseases or conditions, including inflammatory diseases or conditions, using a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
Abstract: One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least ½ hour prior to administration, no food at least 1 hour prior to administration, no food at least 1½ hours prior to administration, no food at least 2 hours prior to administration, no food at least 2½ hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.
Type:
Grant
Filed:
August 20, 2021
Date of Patent:
October 17, 2023
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
Type:
Grant
Filed:
January 3, 2023
Date of Patent:
September 19, 2023
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Type:
Grant
Filed:
August 26, 2019
Date of Patent:
August 29, 2023
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Type:
Grant
Filed:
June 28, 2021
Date of Patent:
June 6, 2023
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Grant
Filed:
February 8, 2021
Date of Patent:
April 25, 2023
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: The invention relates generally to improvements in the treatment of psychotic symptoms, and more particularly, to improvements in the identification of an individual or a population of individuals for whom treatment with iloperidone, an iloperidone metabolite, or pharmaceutically-acceptable salts thereof may provide a particular benefit in treating an individual's psychotic symptoms based on the individual's genotype at the PPEF2 locus.
Type:
Grant
Filed:
October 14, 2020
Date of Patent:
March 21, 2023
Assignee:
Vanda Pharmaceuticals Inc.
Inventors:
Sandra Smieszek, Mihael H. Polymeropoulos
Abstract: A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
Type:
Grant
Filed:
November 17, 2021
Date of Patent:
January 31, 2023
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
Abstract: The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual.
Type:
Grant
Filed:
September 4, 2014
Date of Patent:
October 4, 2022
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan